{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:25:13Z","timestamp":1785252313098,"version":"3.55.0"},"reference-count":76,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science (JSPS)","award":["20K17585"],"award-info":[{"award-number":["20K17585"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Inappropriate mineralocorticoid receptor (MR) activation in different cardiovascular cell types has deleterious effects on cardiac remodeling and function. Therefore, MR inhibition is a crucial pharmacological strategy to overcome cardiovascular dysfunction. Despite efficient blockade of MR with steroidal MR antagonists (MRAs), their clinical application is unsatisfactory due to the adverse effects. Newer non-steroidal MRAs with greater potency could be suitable for clinical application, especially in patients with type 2 diabetes mellitus and chronic kidney disease. Although clinical evidence has shown the beneficial effects of non-steroidal MRAs on cardiovascular outcomes in patients with heart failure with reduced ejection fraction, clinical trials are ongoing to evaluate the efficacy of heart failure with preserved ejection fraction. Therefore, comparative pharmacological characterization of non-steroidal MRAs over classic steroidal MRAs is crucial. Here, we summarize the pre-clinical evidence of non-steroidal MRAs, which suggests an improvement in cardiac dysfunction, as well as the underlying molecular mechanisms in animal models mimicking different clinical conditions. In addition, we discuss up-to-date information from clinical trials regarding the beneficial effects of non-steroidal MRAs on meaningful cardiovascular outcomes. Both pre-clinical and clinical evidence support treatment with non-steroidal MRAs in patients with cardiovascular disease.<\/jats:p>","DOI":"10.3390\/ijms24031922","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T02:51:37Z","timestamp":1674096697000},"page":"1922","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-5343","authenticated-orcid":false,"given":"Asadur","family":"Rahman","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourin","family":"Jahan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5432-480X","authenticated-orcid":false,"given":"Md Tanvir","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Hygiene, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5971-820X","authenticated-orcid":false,"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.hfc.2019.06.007","article-title":"Hypertension and Heart Failure","volume":"15","author":"Slivnick","year":"2019","journal-title":"Heart Fail. Clin."},{"key":"ref_3","unstructured":"Hajouli, S., and Ludhwani, D. (2022, December 20). Heart Failure And Ejection Fraction, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553115\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2012.11.027","article-title":"Risk Factors for Hospitalization Among Older Persons Newly Diagnosed with Heart Failure: The Cardiovascular Health Study","volume":"61","author":"Chaudhry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1111\/bph.15708","article-title":"Mineralocorticoid receptor in cardiovascular diseases\u2014Clinical trials and mechanistic insights","volume":"179","author":"Bauersachs","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00424-008-0616-0","article-title":"Actions of aldosterone in the cardiovascular system: The good, the bad, and the ugly?","volume":"458","author":"Gekle","year":"2009","journal-title":"Pflugers Arch."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure","volume":"341","author":"Ertram","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"ref_11","first-page":"10","article-title":"Spironolactone in heart failure with preserved ejection fraction","volume":"258","author":"Savill","year":"2014","journal-title":"Practitioner"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: Head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Kolkhof","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"bqab105","DOI":"10.1210\/endocr\/bqab105","article-title":"The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor\u2013Directed Therapies in Heart Failure","volume":"162","author":"Young","year":"2021","journal-title":"Endocrinology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_16","first-page":"487","article-title":"The expanding class of mineralocorticoid receptor modulators: New ligands for kidney, cardiac, vascular, systemic and behavioral selective actions","volume":"16","year":"2020","journal-title":"Acta Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","volume":"769","author":"Arai","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","article-title":"Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys","volume":"47","author":"Yamada","year":"2017","journal-title":"Xenobiotica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/1873-3468.13746","article-title":"Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150)","volume":"594","author":"Takahashi","year":"2020","journal-title":"FEBS Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","article-title":"High Blood Pressure and Cardiovascular Disease","volume":"75","author":"Fuchs","year":"2020","journal-title":"Hypertension"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.HYP.0000203148.42892.7a","article-title":"Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts","volume":"47","author":"Kobayashi","year":"2006","journal-title":"Hypertension"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rahman, A., Sawano, T., Sen, A., Hossain, A., Jahan, N., Kobara, H., Masaki, T., Kosaka, S., Kitada, K., and Nakano, D. (2021). Cardioprotective effects of a nonsteroidal mineralocorticoid receptor blocker, esaxerenone, in dahl salt-sensitive hypertensive rats. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042069"},{"key":"ref_28","first-page":"642","article-title":"Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Transl. Res. Res. Artic. Am. J. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Somoza","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/ehf2.13219","article-title":"Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice","volume":"8","author":"Djerada","year":"2021","journal-title":"ESC Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","article-title":"Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy","volume":"67","author":"Grune","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"R1597","DOI":"10.1152\/ajpregu.00825.2009","article-title":"Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload","volume":"298","author":"Fliegner","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone\u2019s Antifibrotic Activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1161\/01.HYP.0000215579.81408.8e","article-title":"Development of heart failure in chronic hypertensive Dahl rats: Focus on heart failure with preserved ejection fraction","volume":"47","author":"Klotz","year":"2006","journal-title":"Hypertension"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/dom.13393","article-title":"Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction","volume":"20","author":"Lachaux","year":"2018","journal-title":"Diabetes. Obes. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","article-title":"Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice","volume":"121","author":"Bonnard","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_38","first-page":"62","article-title":"Cardiac Remodeling: Concepts, Clinical Impact, PathophysiologicalMechanisms and Pharmacologic Treatment","volume":"106","author":"Azevedo","year":"2016","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ncpcardio0158","article-title":"Mechanisms of disease: Pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease","volume":"2","author":"Querejeta","year":"2005","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.115.06530","article-title":"Deoxycorticosterone Acetate\/Salt-Induced Cardiac But Not Renal Injury Is Mediated By Endothelial Mineralocorticoid Receptors Independently From Blood Pressure","volume":"67","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Dutzmann, J., Musmann, R.J., Haertl\u00e9, M., Daniel, J.M., Sonnenschein, K., Sch\u00e4fer, A., Kolkhof, P., Bauersachs, J., and Sedding, D.G. (2017). The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184888"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.freeradbiomed.2012.05.011","article-title":"Aldosterone, oxidative stress, and NF-\u03baB activation in hypertension-related cardiovascular and renal diseases","volume":"53","author":"Queisser","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_43","first-page":"275","article-title":"Roles of oxidative stress and the mineralocorticoid receptor in cardiac pathology in a rat model of metabolic syndrome","volume":"77","author":"Takahashi","year":"2015","journal-title":"Nagoya J. Med. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Briones, A.M., and Touyz, R.M. (2019). Aldosterone\/MR Signaling, Oxidative Stress, and Vascular Dysfunction. Aldosterone-Mineralocorticoid Receptor-Cell Biology to Translational Medicine, IntechOpen Limited.","DOI":"10.5772\/intechopen.87225"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: Role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Li, C., Zhang, Y.Y., Frieler, R.A., Zheng, X.J., Zhang, W.C., Sun, X.N., Yang, Q.Z., Ma, S.M., Huang, B., and Berger, S. (2014). Myeloid Mineralocorticoid Receptor Deficiency Inhibits Aortic Constriction-Induced Cardiac Hypertrophy in Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110950"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","article-title":"Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis","volume":"60","author":"Rickard","year":"2012","journal-title":"Hypertension"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.steroids.2014.04.005","article-title":"Mineralocorticoid Receptors in Immune Cells; Emerging Role in Cardiovascular Disease","volume":"91","author":"Bene","year":"2014","journal-title":"Steroids"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Estrela","year":"2018","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R879","DOI":"10.1152\/ajpregu.00075.2014","article-title":"Cardiac macrophages and apoptosis after myocardial infarction: Effects of central MR blockade","volume":"307","author":"Rafatian","year":"2014","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1159\/000524940","article-title":"Finerenone reduces renal RORgt gd T-Cells and protects against cardiorenal damage","volume":"53","author":"Luettges","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"ref_54","first-page":"e21314","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells","volume":"35","author":"Perrot","year":"2021","journal-title":"FASEB J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","article-title":"Cardiac Fibrosis: The Fibroblast Awakens","volume":"118","author":"Travers","year":"2016","journal-title":"Circ. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1042\/CS20080247","article-title":"Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart","volume":"116","author":"Wilson","year":"2009","journal-title":"Clin. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1248\/bpb.b15-00402","article-title":"Mangiferin inhibits renal urate reabsorption by modulating urate transporters in experimental hyperuricemia","volume":"38","author":"Yang","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCHEARTFAILURE.120.007279","article-title":"Mineralocorticoid Receptor in Smooth Muscle Contributes to Pressure Overload-Induced Heart Failure","volume":"14","author":"Kim","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e000018","DOI":"10.1161\/JAHA.112.000018","article-title":"Aldosterone Increases Early Atherosclerosis and Promotes Plaque Inflammation Through a Placental Growth Factor-Dependent Mechanism","volume":"2","author":"McGraw","year":"2013","journal-title":"J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"112227","DOI":"10.1016\/j.biopha.2021.112227","article-title":"Inclisiran in lipid management: A Literature overview and future perspectives","volume":"143","author":"Scicchitano","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000506275","article-title":"Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Fr\u00f6mter Rats, a Genetic Model of Chronic Kidney Disease","volume":"51","author":"Schulz","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Iwahana, T., Saito, Y., Okada, S., Kato, H., Ono, R., and Kobayashi, Y. (2021). Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0259485"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/HYPERTENSIONAHA.121.17440","article-title":"Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments","volume":"78","author":"Kario","year":"2021","journal-title":"Hypertension"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/HYPERTENSIONAHA.120.14790","article-title":"Cardiovascular Event Risks Associated with Masked Nocturnal Hypertension Defined by Home Blood Pressure Monitoring in the J-HOP Nocturnal Blood Pressure Study","volume":"76","author":"Fujiwara","year":"2020","journal-title":"Hypertension"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41440-021-00756-5","article-title":"Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes","volume":"45","author":"Kario","year":"2022","journal-title":"Hypertens. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and\/or Chronic Kidney Disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","article-title":"Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Alonso","year":"2011","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3724\/SP.J.1263.2011.00141","article-title":"Cardiac remodeling as a consequence of atrial fibrillation: An anatomical study of perfusion-fixed human heart specimens","volume":"8","author":"Rolfes","year":"2011","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"H1126","DOI":"10.1152\/ajpheart.00898.2014","article-title":"Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice","volume":"308","author":"Bostick","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/1922\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:09:31Z","timestamp":1760119771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/1922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24031922"],"URL":"https:\/\/doi.org\/10.3390\/ijms24031922","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]}}}